Article
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas.
Nature - 1 Jan 2025
Monje Michelle, Mahdi Jasia, Majzner Robbie, Yeom Kristen W, Schultz Liora M, Richards Rebecca M, Barsan Valentin, Song Kun-Wei, Kamens Jen, Baggott Christina, Kunicki Michael, Rietberg Skyler P, Lim Alexandria Sung, Reschke Agnes, Mavroukakis Sharon, Egeler Emily, Moon Jennifer, Patel Shabnum, Chinnasamy Harshini, Erickson Courtney, Jacobs Ashley, Duh Allison K, Tunuguntla Ramya, Klysz Dorota Danuta, Fowler Carley, Green Sean, Beebe Barbara, Carr Casey, Fujimoto Michelle, Brown Annie Kathleen, Petersen Ann-Louise G, McIntyre Catherine, Siddiqui Aman, Lepori-Bui Nadia, Villar Katlin, Pham Kymhuynh, Bove Rachel, Musa Eric, Reynolds Warren D, Kuo Adam, Prabhu Snehit, Rasmussen Lindsey, Cornell Timothy T, Partap Sonia, Fisher Paul G, Campen Cynthia J, Grant Gerald, Prolo Laura, Ye Xiaobu, Sahaf Bita, Davis Kara L, Feldman Steven A, Ramakrishna Sneha, Mackall Crystal
Abstract excerpt
H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the disialoganglioside GD2 (ref. 1). Chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) eradicated DMGs in preclinical models1. Arm A of Phase I trial no. NCT04196413 (ref. 2) administered one intravenous (IV) dose of autologous GD2-CART to patients with H3K27M-mutant pontine (DIPG) or spinal DMG (sDMG) at two dose levels (DL1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.